Genetron Health: Chao Tang and Shan Fu
Genetron Health has appointed Chao Tang and Shan Fu to its board of directors. Tang replaces Weiwu He, who had served as chairman of the board beginning in May 2015. Fu replaces Weidong Liu, who served as board director starting November 2019. According to Genetron, both He and Liu have resigned from its board due to personal reasons. He has since been appointed chairman emeritus in recognition of his prior contributions.
Tang is a chair professor of physics and systems biology at Peking University. His current research interest is at the interface between physics and biology. He is a fellow of the American Physical Society, an academician of the Chinese Academy of Sciences, the founding director of the Center for Quantitative Biology at Peking University and the founding co-editor-in-chief of the journal Quantitative Biology. He had his undergraduate training at the University of Science and Technology of China and received a PhD in physics from the University of Chicago.
Fu has previously served as joint CEO of Vivo Capital, beginning in October 2013. Prior to Vivo, he worked as the chief representative of China at Blackstone Group, and in leadership positions at several other firms. Fu received both his BA and master's degree in history from Peking University.
Genetron also said that it has named Sizhen Wang, the firm's co-founder, chairman, and CEO, as its new board chairman. In addition, effective June 30, Kevin Ying Hong will become the firm's senior advisor.